Type 1 Diabetes Med-Tech Commercial Strategy
Identifying the best approach for the NHS in relation to absorbing the cost impact of the initial recommendations stemming from the NICE MTA undertaken for Type 1 Diabetes hybrid closed-loop medical technology
Buyer
NHS England
Value
£90,000
Published
6 Mar 2023
Closes
10 Feb 2023
Procurement details
Source
Contracts Finder
Region
London
Procurement method
Selective
Category
Services
Contract starts
13 Feb 2023
Contract ends
31 Mar 2023
CPV classifications
79411100
Business development consultancy services
Lots
Lot default Type 1 Diabetes Med-Tech Commercial Strategy
£90,000
Identifying the best approach for the NHS in relation to absorbing the cost impact of the initial recommendations stemming from the NICE MTA undertaken for Type 1 Diabetes hybrid closed-loop medical technology
Delivery: England · United Kingdom, England, United Kingdom
Documents
Unlock document linkAwarded contract notice on Contracts Finder
6 Mar 2023
Awarded contract notice on Contracts Finder
Award notice · Web page
HSSF Order Form - BC 16165 Type 1 Diabetes Med-Tech Commercial Strategy (004) CF_Redacted
Not provided
HSSF Order Form - BC 16165 Type 1 Diabetes Med-Tech Commercial Strategy (004) CF_Redacted
Contains public sector information licensed under the Open Government Licence v3.0.